DUSP29 is a dual-specificity phosphatase that dephosphorylates phosphotyrosine, phosphoserine, and phosphothreonine residues, with preference for phosphotyrosine substrates 1. The enzyme is expressed primarily in skeletal muscle, liver, and adipose tissue, where it modulates intracellular signaling cascades. DUSP29 negatively regulates the ERK1/2 branch of the MAP kinase pathway and affects AMPK signaling, an energy sensor protein kinase involved in glucose homeostasis. During neurogenic skeletal muscle atrophy, DUSP29 expression is significantly upregulated in differentiated myotubes and is transcriptionally induced by myogenic regulatory factors including MyoD and myogenin 2. The phosphatase appears to modulate muscle cell differentiation and development through MAPK signaling suppression. Additionally, DUSP29 overexpression attenuates glucocorticoid receptor activity in muscle cells, potentially influencing corticosteroid-induced atrophy responses 2. Given DUSP29's role in regulating kinase signaling pathways implicated in metabolic and inflammatory disease, dual-specificity phosphatases broadly have emerged as potential therapeutic targets for conditions including cancer, diabetes, and inflammatory disorders 3. However, the precise therapeutic utility of DUSP29 inhibition or modulation remains to be established.